Shares of Interactive Intelligence Inc. surged Tuesday after the communications software maker reported preliminary third-quarter results and projected that revenue will grow 20 percent this year.
Indianapolis-based WellPoint Inc. and competing U.S. health insurers approved $10 billion in stock repurchases in the past year, a concern to investors who say buybacks failed to increase share prices and who want more spent on dividends.
Opposition by preferred shareholders has Emmis shares trading at more than 30 percent below the buyout price of $2.40 per
share.
Indianapolis-based WellPoint Inc. became the third U.S. health insurer this month to increase its 2010 profit forecast, stirring
investor concern that state and federal regulators may increase scrutiny of industry pricing.
High expectations already are baked into HHGregg Inc.’s stock price, which has doubled since last May. A disappointment could
spawn a sell-off.
Lilly shareholders are set to gather Monday in Indianapolis to hear an update on the company’s performance, including
how it will keep paying its generous dividend during the lean years after Zyprexa’s patent expiration.
Sardar Biglari has copied some of the trademarks of his investing idol, Warren Buffett, including a folksy annual letter to
shareholders. But Biglari is just starting his career and already is showing signs of taking a different approach than that
of the Oracle of Omaha.
As shareholders gather April 19 for Eli Lilly and Co.’s annual meeting, more of them than ever will come with an unusual question:
Will Lilly be able to keep paying its dividend?
CEO Donald Brown saw a 32.4-percent increase in total compensation last year as the software-maker's shares soared 169
percent.
Shares in General Growth Properties Inc., the second-biggest U.S. mall owner, fell as much as 6.7 percent Monday morning after
a newsletter report that Simon Property Group Inc. may abandon a takeover bid for its smaller rival.
Once the nation’s wealthiest foundation, Indianapolis-based Lilly Endowment now ranks ninth among its grant-making
peers. The endowment’s value fell 15 percent last year, to an estimated $4.8 billion.
Lilly Endowment’s resistance to diversify its holdings reached a new height last year, as it failed to sell a single share
of the underperforming Eli Lilly and Co. stock while the broader market surged.
CEO Bryan Bedford remains at the helm, but shares of Republic Airways have fallen nearly 30 percent following the departure
of an executive deemed key to the operation
of the regional airline’s first two branded carriers, Frontier Airlines and Midwest Airlines.
Columbus-based diesel engine maker Cummins Inc. posted its most profitable fourth quarter in company history, thanks to a
rush on engines that won’t have to conform to new emission standards.
With the stunning victory of Republican Scott Brown in the Massachusetts election for U.S. Senate, Wall Street analysts
expect to see a "run" on health care stocks.
The Steak n Shake Co.’s unusual plan to initiate a reverse stock split has the support of at least one local investment
adviser,
if in fact the company’s CEO is attempting to model it after Warren Buffett’s holding company, Berkshire Hathaway.
The Steak n Shake Co., in an unusual gambit, plans to initiate a reverse stock split that would reduce its number of shares
outstanding from almost 29 million to just 1.4 million and boost its per-share price from roughly $12 to $240.
Shares of Indianapolis-based Emmis Communications Corp. closed Monday at $1.53, the 10th straight day the stock has finished
trading above $1—preserving the company’s listing on the NASDAQ stock exchange.
Shares of Indianapolis-based Emmis Communications Corp. closed Monday at $1.53, the 10th straight day the stock has finished
trading above $1—preserving the company’s listing on the NASDAQ stock exchange, but big challenges remain for the locally
based owner of radio stations and magazines.
For the first time publicly, Eli Lilly and Co. officials admitted the obvious: Their pipeline products
aren’t likely to offset the revenue the company will lose after its two bestsellers, Zyprexa and Cymbalta, lose patent exclusivity.
